Outlook Therapeutics (OTLK) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 51.3% versus a loss of 71.3%. Over five years, TNYA leads with a -97.2% price change compared with -98.7% for OTLK. Outlook Therapeutics is the larger company by market cap ($145.8 million vs $130.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | TNYA |
|---|---|---|
| Share price | $0.5989 | $0.5803 |
| Market cap | $145.80M | $130.12M |
| 1-day change | +6.19% | +6.63% |
| YTD return | -62.09% | -18.50% |
| 1-year return | -51.31% | -71.27% |
| 5-year return | -98.66% | -97.18% |
| EPS (TTM) | $-0.74 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $2.35 |
| 52-week low | $0.161 | $0.521 |
| Distance from 52-week high | -76.40% | -75.31% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +739.87% | +451.44% |
| Average volume | 13.43M | 2.27M |
| Shares outstanding | 243.45M | 224.23M |
| Employees | 17 | 70 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OTLK has outperformed TNYA by 20.0 percentage points over the past year.
- The two companies sit in different sectors: Outlook Therapeutics in Healthcare and Tenaya Therapeutics in Health Care.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Healthcare · Biotechnology · 17 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
OTLK vs TNYA FAQ
Which is bigger, Outlook Therapeutics or Tenaya Therapeutics?
Outlook Therapeutics (OTLK) is larger, with a market capitalization of $145.80M compared with $130.12M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, OTLK or TNYA?
OTLK returned -51.31% over the past 12 months, compared with -71.27% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and Tenaya Therapeutics in the same industry?
No. Outlook Therapeutics is in the Healthcare sector, while Tenaya Therapeutics is in Health Care.